2026 ICD-10-CM Diagnosis Code D89.0Polyclonal hypergammaglobulinemia
ICD-10-CM Codes›D50–D89›D80-D89›D89
- Billable — Valid for Submission
- Chronic Condition
D89.0 is a billable ICD-10-CM diagnosis code for polyclonal hypergammaglobulinemia. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 814 through 816. Coders also document this condition as benign primary hypergammaglobulinemic purpura. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Immunity disorders.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Benign primary hypergammaglobulinemic purpura
- Hyperglobulinemic purpura
- Polyclonal gammopathy
- Polyclonal hypergammaglobulinemia
- Waldenstrom's hypergammaglobulinemic purpura
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Benign hypergammaglobulinemic purpura
- Polyclonal gammopathy NOS
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Gammopathy (of undetermined significance [MGUS]) - D47.2
- polyclonal - D89.0
- Hypergammaglobulinemia - D89.2
- polyclonal - D89.0
- Waldenström - D89.0
- hypergammaglobulinemia - D89.0
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Gammopathy(of undetermined significance [MGUS])
- polyclonal
- Hypergammaglobulinemia
- polyclonal
- Hypergammaglobulinemia
- Waldenström
- Purpura
- hypergammaglobulinemic (benign) (Waldenström)
- Waldenström
- hypergammaglobulinemia
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Lymphadenopathy with Polyclonal Hypergammaglobulinemia|Lymphoadenopathy w/ polyclonal|Lymphoadenopathy with polyclonal hypergammaglobulinemia
a finding indicating the presence of enlarged lymph nodes and associated polyclonal hypergammaglobulinemia.Polyclonal Hypergammaglobulinemia
a laboratory test result indicating abnormally high proliferation of gamma globulins in the blood originating from multiple cell lines.
Patient EducationClinical
Immune System and Disorders
Your immune system is a complex network of cells, tissues, and organs. Together they help the body fight infections and other diseases.
The full article covers:
- What is the immune system?
- What are the parts of the immune system?
- How does the immune system work?
- What are the types of immunity?
- What can go wrong with the immune system?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D89.0 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D89.0Overview
Is D89.0 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report polyclonal hypergammaglobulinemia on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does D89.0 group to?
When polyclonal hypergammaglobulinemia is the principal diagnosis on an inpatient stay, it groups to MS-DRG 814, 815, 816, with relative weights from 0.6320 to 2.1267 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of D89.0?
Under the General Equivalence Mappings, polyclonal hypergammaglobulinemia converts to ICD-9-CM 273.0 (polyclon hypergammaglobu). The mapping is a direct match.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
